Informationen:
Fehler:
ID
26057
Beschreibung
A Prospective, Single-Arm Study to Evaluate the Efficacy and Safety of Zoladex 3.6mg Combined With CEF Chemotherapy as Neo-Adjuvant Therapy in Hormone Responsive, Premenopausal, Operable Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00488722
Link
https://clinicaltrials.gov/show/NCT00488722
Stichworte
Versionen (1)
- 05.10.17 05.10.17 -
Rechteinhaber
See clinicaltrials.gov
Hochgeladen am
5. Oktober 2017
DOI
Für eine Beantragung loggen Sie sich ein.
Lizenz
Creative Commons BY 4.0
Modell Kommentare :
Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.
Itemgroup Kommentare für :
Item Kommentare für :
Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.
Eligibility Breast Cancer NCT00488722
Eligibility Breast Cancer NCT00488722
- StudyEvent: Eligibility
Ähnliche Modelle
Eligibility Breast Cancer NCT00488722
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Informed Consent
Item
1. provision of informed consent
boolean
C0021430 (UMLS CUI [1])
Breast Carcinoma
Item
2. pathological confirmation of breast cancer
boolean
C0678222 (UMLS CUI [1])
TNM clinical staging
Item
3. tumor stage(tnm):t2-4bn0-3m0
boolean
C3258246 (UMLS CUI [1])
Estrogen receptor positive | Progesterone receptor positive
Item
4. er(+) and/or pr(+).
boolean
C0279754 (UMLS CUI [1])
C0279759 (UMLS CUI [2])
C0279759 (UMLS CUI [2])
Premenopausal state
Item
5. premenopausal woman.
boolean
C0232969 (UMLS CUI [1])
Age
Item
6. age≥40 years
boolean
C0001779 (UMLS CUI [1])
Measurable Disease
Item
7. measurable disease as per recist criteria
boolean
C1513041 (UMLS CUI [1])
Karnofsky Performance Status
Item
8. karnofsky≥70
boolean
C0206065 (UMLS CUI [1])
Laboratory criteria
Item
9. labratory criteria:
boolean
C0022877 (UMLS CUI [1,1])
C0243161 (UMLS CUI [1,2])
C0243161 (UMLS CUI [1,2])
Platelet Count measurement
Item
plt≥100*109/l
boolean
C0032181 (UMLS CUI [1])
White Blood Cell Count procedure
Item
wbc≥4000/mm3
boolean
C0023508 (UMLS CUI [1])
Hemoglobin measurement
Item
hgb≥10g/dl
boolean
C0518015 (UMLS CUI [1])
Alanine aminotransferase measurement | Aspartate aminotransferase measurement
Item
alt and ast<2*uln
boolean
C0201836 (UMLS CUI [1])
C0201899 (UMLS CUI [2])
C0201899 (UMLS CUI [2])
Neoplasm Metastasis
Item
1. presence of metastatic disease.
boolean
C0027627 (UMLS CUI [1])
Inflammatory Breast Carcinoma
Item
2. inflammatory breast cancer.
boolean
C0278601 (UMLS CUI [1])
bilateral breast cancer
Item
3. bilateral breast cancer.
boolean
C0281267 (UMLS CUI [1])
Chemotherapy Breast Carcinoma | Hormone Therapy Breast Carcinoma
Item
4. previous chemotherapy or hormonal therapyfor current breast neoplasm.
boolean
C0392920 (UMLS CUI [1,1])
C0678222 (UMLS CUI [1,2])
C0279025 (UMLS CUI [2,1])
C0678222 (UMLS CUI [2,2])
C0678222 (UMLS CUI [1,2])
C0279025 (UMLS CUI [2,1])
C0678222 (UMLS CUI [2,2])
Malignant Neoplasms
Item
5. other malignant tumor (concurrent or previous).
boolean
C0006826 (UMLS CUI [1])
Pregnancy
Item
6. pregnant woman.
boolean
C0032961 (UMLS CUI [1])
Hypersensitivity Pharmaceutical Preparations CEF regimen | Hypersensitivity Zoladex Ingredient
Item
7. hypersensitive to any drug in cef regimen or any ingredient of zoladex.
boolean
C0020517 (UMLS CUI [1,1])
C0013227 (UMLS CUI [1,2])
C0248241 (UMLS CUI [1,3])
C0020517 (UMLS CUI [2,1])
C0149473 (UMLS CUI [2,2])
C1550600 (UMLS CUI [2,3])
C0013227 (UMLS CUI [1,2])
C0248241 (UMLS CUI [1,3])
C0020517 (UMLS CUI [2,1])
C0149473 (UMLS CUI [2,2])
C1550600 (UMLS CUI [2,3])
Systemic disease Severe | Medical contraindication Chemotherapy Regimen
Item
8. any severe systemic disease contraindicating chemotherapy.
boolean
C0442893 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
C1301624 (UMLS CUI [2,1])
C0392920 (UMLS CUI [2,2])
C0205082 (UMLS CUI [1,2])
C1301624 (UMLS CUI [2,1])
C0392920 (UMLS CUI [2,2])